Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1617 - Analysis of Angiogenesis Biomarkers for Ramucirumab (RAM) Efficacy in Patients with Metastatic Colorectal Cancer (mCRC) from RAISE, a Global, Randomized, Double-Blind, Phase 3 Study

Date

09 Sep 2017

Session

Poster display session

Presenters

Josep Tabernero

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

J. Tabernero1, R.R. Hozak2, T. Yoshino3, A.L. Cohn4, R. Obermannova5, G. Bodoky6, R. Garcia-Carbonero7, T. Ciuleanu8, D.C. Portnoy9, K. Muro10, H. Ouyang11, S. Melemed12, D. Ferry13, F. Nasroulah14, E. Van Cutsem15

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, Universitat Autònoma de Barcelona, 08035 - Barcelona/ES
  • 2 Late-phase Oncology Tailoring Biomarker Statistics, Eli Lilly and Company, Indianapolis/US
  • 3 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4 Medical Oncology / Hematology, Rocky Mountain Cancer Center/US Oncology, 80111 - Denver/US
  • 5 Department Of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 65653 - Brno/CZ
  • 6 Clinical Oncology, Combined Szent István and Szent László Hospitals, 1097 - Budapest/HU
  • 7 Medical Oncology Department, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 8 Medical Oncology, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj-Napoca/RO
  • 9 Medical Oncology, West Clinic, 38138 - Memphis/US
  • 10 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 11 Medical Oncology, Eli Lilly and Company, Indianapolis/US
  • 12 Oncology, Eli Lilly and Company, Indianapolis/US
  • 13 Oncology, Eli Lilly and Company, Bridgewater/US
  • 14 Medical Oncology, Eli Lilly and Company, Buenos Aires/AR
  • 15 Digestive Oncology, University Hospital Gasthuisberg-University of Leuven, Leuven/BE
More

Resources

Abstract 1617

Background

The RAISE trial (NCT01183780) demonstrated that RAM plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus FOLFIRI (PBO) as second-line mCRC treatment. Despite multiple approved anticancer treatments targeting angiogenesis, there are currently no predictive markers to guide patient selection. The extensive RAISE biomarker program assessed the association of multiple candidate biomarkers with RAM efficacy outcomes.

Methods

Plasma and tumor tissue collection was mandatory in the RAISE trial. Analyses were performed using exploratory assays to assess the correlations of the baseline marker levels (vascular endothelial growth factor [VEGF]-C and D; soluble vascular endothelial growth factor receptor [sVEGFR]1, 2, and 3; and VEGFR2 immunohistochemistry in tumor tissue) with clinical outcomes. Cox regression analyses adjusted for stratification factors were performed for each marker.

Results

Biomarker results were available from >80% of patients. Among the candidate biomarkers analyzed, only VEGF-D levels had a consistent and statistically significant association with OS and PFS, suggesting a predictive relationship. Higher levels were associated with improved RAM efficacy (Table). This relationship was consistent across the full range of VEGF-D levels.Table:

555P Correlation of VEGF-D with Efficacy Outcomes: based on cut point from exploratory subset. Results below from combined exploratory + confirmatory groups

OSPFS
Prespecified cut point≥115 pg/mL

Conclusions

These analyses from RAISE identified VEGF-D as a potential predictive marker for RAM efficacy in mCRC. Further investigation of this relationship is being pursued.

Clinical trial identification

NCT01183780

Legal entity responsible for the study

Eli Lilly and Company

Funding

Eli Lilly and Company

Disclosure

J. Tabernero: Consultant/advisory board roles for Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Eli Lilly and Company, Imclone, Merck Serono, MSD, Novartis, Pfizer, Roche, Sanofi, Symphogen, and Taiho. R.R. Hozak: Employee and stockholder of Eli Lilly and Company. T. Yoshino: Research funding from GlaxoSmithKline K.K. and Boehringer Ingelheim GmbH. A.L. Cohn: Speaker’s bureau for Merrimack and consultant for BMS and Genentech. R. Obermannova: Consultant for Amgen, Roche, and Bayer; on the speaker’s bureau for Amgen, Roche, and Eli Lilly and Company; research funding from Merck. T-E. Ciuleanu: Advisory role for Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Serono, Servier and Teva. D.C. Portnoy: Consultant for Eli Lilly and Company. K. Muro: Corporate-sponsored research for Shionogi & Co Ltd., MSD KK, Daiichi Sankyo Co Ltd, and Gilead Sciences and honoraria for lectures for Chugai, Takeda, Taiho, Merck Serono, Eli Lilly Japan, and Yakult Honsha. H. Ouyang: Former employee and current stockholder of Eli Lilly and Company. S. Melemed: Employee and stockholder of Eli Lilly and Company. D. Ferry: Employee and stockholder of Eli Lilly and Company. F. Nasroulah: Full-time employee of Eli Lilly and Company. E. Van Cutsem: Research grants and advisor for Amgen, Bayer, Boehringer, Celgene, Eli Lilly and Company, Ipsen, Merck, Merckserono, Novartis, Roche, Sanofi, and Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.